At ESMO Congress 2019, phase III FLAURA trial is one of the much awaited studies in lung cancer, according to Alessandra Curioni Fontecedro, University Hospital Zürich, Switzerland and Associate Editor of the Daily Reporter. Overall survival data will be presented at the first Presidential Symposium at the congress on Saturday 28 September.
Practice-changing results in NSCLC are expected
